Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

The traditional concept believes that the etiology of neonatal respiratory distress syndrome (RDS) is immature development of lung,especially the surfactant synthesis system,and RDS is still one of the major causes of mortality and morbidity in newborns, especially premature infants.In recent years, using pulmonary surfactant replacement therapy (PS treatment) in the treatment of respiratory distress syndrome (RDS) is a major breakthrough in neonatal medicine.Combined with clinical practice and experience,and through Meta analysis of related randomized controlled trials (RCTs),it confirms that natural surfactant treatment can reduce mortality,the incidence of pulmonary air leaks (pneumothorax and interstitial lung emphysema),and the incidence of bronchopulmonary dysplasia (BPD) or 28-day-old mortality.For RDS in preterm infants whose gestation is <35 weeks ,surfactant replacement therapy is also more effective than in nearly term and full term infants.Therefore, in the analysis of cases of different gestational age groups,the investigators should focus on the study of premature infants cases.Due to less relevant research for using PS treatment to cure newborn RDS in high altitude area,this retrospective study conducts statistics and analysis of recently three-year cases in some hospital of high altitude area,to explore the treatment effect of the high altitude region and the impact of altitude on the treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: Newborn
Maximum Age: 1 day
View:

• the preterm infants less than 37 weeks were included in the study;diagnosed with NRDS

Locations
Other Locations
China
Department of Pediatrics, Daping Hospital, Third Military Medical University
Recruiting
Chongqing
Contact Information
Primary
Ma Juan, MD
petshi530@vip.163.com
13508300283
Backup
Chen Long, PhD,MD
476679422@qq.com
13883559467
Time Frame
Start Date: March 1, 2020
Estimated Completion Date: December 1, 2022
Participants
Target number of participants: 200
Sponsors
Leads: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborators: the first people hospital of Tibet autonomous region, the people hospital of Linzhi, the first people hospital of Lasa, the first people hospital of Shigatse, the second people hospital of Lasa, the people hospital of Laqu

This content was sourced from clinicaltrials.gov

Similar Clinical Trials